Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 52-week Multicenter, Randomized, Double-masked, 2-arm Parallel Study to Compare Efficacy, Safety and Immunogenicity of SOK583A1 to Eylea®, Administered Intravitreally, in Patients With Neovascular Age-related Macular Degeneration

NCT04864834 is registered in ClinicalTrials.gov with Sandoz as lead sponsor.

NCT NCT04864834
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04864834 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 52-week Multicenter, Randomized, Double-masked, 2-arm Parallel Study to Compare Efficacy, Safety and Immunogenicity of SOK583A1 to Eylea®, Administered Intravitreally, in Patients With Neovascular Age-related Macular Degeneration
Lead sponsor
Sandoz
Phase
Phase 3
Overall status
Completed
Start date
May 12, 2021
Completion date
May 10, 2023
Enrollment
485 (actual)
Sites
102

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular age-related macular degeneration